NCT06393972View on ClinicalTrials.gov

The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Glucocorticoid Resistant ICIs-related Myocarditis

Interventions

DRUG

Tofacitinib 5 MG BID

Tofacitinib 5 MG BID

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER